Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Rx Risk Advisor Seligman Joins From DoE, Reports To CDER's Galson

Executive Summary

Department of Energy Deputy Assistant Secretary for Health Studies Paul Seligman, MD, will handle pharmaceutical risk management initiatives at FDA in his new position as senior advisor.

You may also be interested in...

CDER Deputy Director Galson To Head Drug Center For Several Months

Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months

Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.

FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts